Showing 3651-3660 of 20434 results for "".
- CHMP Issues Positive Opinion for Redemplo in Adult FCShttps://reachmd.com/news/chmp-issues-positive-opinion-for-redemplo-in-adult-fcs/2486870/Key Takeaways The CHMP adopted a positive opinion recommending REDEMPLO for adults with familial chylomicronemia syndrome as an adjunct to diet to reduce triglyceride levels. In PALISADE, lower triglycerides and fewer acute pancreatitis cases were repo
- Enzalutamide Improves Overall Survival in Biochemical Recurrencehttps://reachmd.com/news/enzalutamide-improves-overall-survival-in-biochemical-recurrence/2486842/Key Takeaways Combination therapy was associated with longer overall survival than leuprolide alone in the final analysis. Enzalutamide monotherapy was not significantly different from leuprolide alone for overall survival. Descriptive updates
- Novel hs-cTnT Assay Doubles Early Myocardial Infarction Rule-Outhttps://reachmd.com/news/novel-hs-ctnt-assay-doubles-early-myocardial-infarction-rule-out/2486844/Key Takeaways The study-derived threshold below 13 ng/L was associated with more low-risk classification at presentation than the fifth-generation hs-cTnT approach. In external validation, 782 of 1721 patients, or 45.4%, were below 13 ng/L, with NPV 99
- Tucidinostat Plus R-CHOP Improves Event-Free Survival in DEL DLBCLhttps://reachmd.com/news/tucidinostat-plus-r-chop-improves-event-free-survival-in-del-dlbcl/2486810/Key Takeaways Event-free survival was better with tucidinostat plus R-CHOP than with placebo plus R-CHOP. Complete response was observed more often with the tucidinostat-containing regimen. Toxicity was higher with tucidinostat and was general
- Gut Microbiome Patterns Linked to IBS-D Response to Rifaximin, Diethttps://reachmd.com/news/gut-microbiome-patterns-linked-to-ibs-d-response-to-rifaximin-diet/2486812/Key Takeaways Five-week decreases in abdominal pain and bloating were comparable after rifaximin and low FODMAP diet counseling. Baseline microbiome features differed among low FODMAP responders, rifaximin responders, and patients who did not respond t
- Secukinumab In SELUNE: Phase III Lupus Nephritis Readouthttps://reachmd.com/news/secukinumab-in-selune-phase-iii-lupus-nephritis-readout/2486777/Key Takeaways Complete renal response at week 52 was lower with secukinumab than with placebo. No differences were seen across secondary endpoints, and treatment-emergent adverse events were similar between groups. A planned futility analysis
- AI Immune Profiling on Histopathology Slides in Rectal Cancerhttps://reachmd.com/news/ai-immune-profiling-on-histopathology-slides-in-rectal-cancer/2486667/Key Takeaways TIL positivity was associated with longer disease-free and overall survival, while TAM positivity was associated with shorter disease-free survival in the main cohort. Similar directional patterns were described across the additional coho
- Tecovirimat Fails to Improve Key Mpox Outcomes in Phase 3 Trialhttps://reachmd.com/news/tecovirimat-fails-to-improve-key-mpox-outcomes-in-phase-3-trial/2486673/Key Takeaways Tecovirimat was reported as not outperforming placebo on key mpox outcomes in this randomized phase 3 study. The trial enrolled 412 participants, used 2 to 1 randomization, and compared 14 days of tecovirimat with placebo across multiple
- Bisoprolol Did Not Improve Cardiorespiratory Outcomes in COPD Trialhttps://reachmd.com/news/bisoprolol-did-not-improve-cardiorespiratory-outcomes-in-copd-trial/2486643/A recent study reports no overall cardiorespiratory advantage for bisoprolol over placebo in the PACE phase 3 trial among adults with moderately severe COPD. This double-blind, randomized, cont
- THRIVE-AA2: Deuruxolitinib Improves Week 24 SALT20 Responsehttps://reachmd.com/news/thrive-aa2-deuruxolitinib-salt20-response/2486601/Key Takeaways THRIVE-AA2 enrolled adults aged 18 to 65 years with severe chronic alopecia areata and assigned 517 participants to two deuruxolitinib dose groups or placebo. Both deuruxolitinib regimens were associated with higher Week 24 SALT20 respons